CN109071498A - 激酶抑制剂及其制备方法和用途 - Google Patents

激酶抑制剂及其制备方法和用途 Download PDF

Info

Publication number
CN109071498A
CN109071498A CN201880001642.XA CN201880001642A CN109071498A CN 109071498 A CN109071498 A CN 109071498A CN 201880001642 A CN201880001642 A CN 201880001642A CN 109071498 A CN109071498 A CN 109071498A
Authority
CN
China
Prior art keywords
compound
formula
base
alkyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880001642.XA
Other languages
English (en)
Other versions
CN109071498B (zh
Inventor
刘钢
于华
唐建川
杜静
王坤建
刘金明
蔡家强
曾宏
宋宏梅
王利春
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN109071498A publication Critical patent/CN109071498A/zh
Application granted granted Critical
Publication of CN109071498B publication Critical patent/CN109071498B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及凋亡信号调节激酶1(ASK1)抑制剂、包含其的药物组合物、其制备方法和中间体及其用于预防或治疗ASK1介导的疾病的用途。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201880001642.XA 2017-02-16 2018-01-26 激酶抑制剂及其制备方法和用途 Active CN109071498B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017100833536 2017-02-16
CN201710083353 2017-02-16
PCT/CN2018/074263 WO2018149284A1 (zh) 2017-02-16 2018-01-26 激酶抑制剂及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN109071498A true CN109071498A (zh) 2018-12-21
CN109071498B CN109071498B (zh) 2021-03-30

Family

ID=63169688

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880001642.XA Active CN109071498B (zh) 2017-02-16 2018-01-26 激酶抑制剂及其制备方法和用途

Country Status (2)

Country Link
CN (1) CN109071498B (zh)
WO (1) WO2018149284A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071448A (zh) * 2017-01-22 2018-12-21 福建广生堂药业股份有限公司 Ask1抑制剂及其制备方法和应用
CN110294742A (zh) * 2018-03-21 2019-10-01 山东轩竹医药科技有限公司 并环类ask1抑制剂及其应用
CN111808079A (zh) * 2020-08-05 2020-10-23 中国药科大学 吲哚类ask1小分子抑制剂及其制备方法和应用
CN113234053A (zh) * 2021-05-30 2021-08-10 吉林农业大学 裂环羽扇豆烷衍生物及在制备ask1抑制剂中的应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018157277A1 (en) * 2017-02-28 2018-09-07 Eli Lilly And Company Isoquinolin and naphthydrin compounds
JOP20190221A1 (ar) 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
WO2018209354A1 (en) 2017-05-12 2018-11-15 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10253018B2 (en) 2017-05-25 2019-04-09 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10450301B2 (en) 2017-05-25 2019-10-22 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218044A2 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals Inc Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN109265443B (zh) * 2017-07-18 2022-11-29 南京圣和药业股份有限公司 作为ask抑制剂的杂环化合物及其应用
WO2019046186A1 (en) 2017-08-28 2019-03-07 Enanta Pharmaceuticals, Inc. INHIBITORS OF KINASE 1 REGULATING THE APOPTOTIC SIGNAL CONTAINING TETRAZOLES AND METHODS OF USE THEREOF
CN109456308B (zh) * 2017-09-06 2022-11-29 南京圣和药业股份有限公司 作为ask抑制剂的杂环化合物及其应用
CN109956928B (zh) * 2017-12-14 2021-07-09 四川科伦博泰生物医药股份有限公司 吡啶类化合物、其制备方法及用途
WO2019136025A1 (en) 2018-01-02 2019-07-11 Seal Rock Therapeutics, Inc. Ask1 inhibitor compounds and uses thereof
WO2019213239A1 (en) 2018-05-02 2019-11-07 Enanta Pharmaceuticals Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
MX2020011225A (es) 2018-05-02 2021-01-20 Enanta Pharm Inc Tetrazol que contiene inhibidores de la cinasa 1 reguladora de la señal de apoptosis y métodos de uso de los mismos.
WO2020041417A1 (en) 2018-08-22 2020-02-27 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
KR102288434B1 (ko) * 2018-10-18 2021-08-12 에이치케이이노엔 주식회사 신규한 (이소프로필-트리아졸릴)피리디닐 치환된 벤조옥사지논 또는 벤조티아지논 유도체 및 이의 용도
WO2020106707A1 (en) 2018-11-19 2020-05-28 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11466033B2 (en) 2019-03-25 2022-10-11 Enanta Pharmaceuticals, Inc. Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
US20220242850A1 (en) * 2019-07-30 2022-08-04 Janssen Pharmaceutica Nv Phthalazin-1-one derivatives useful as grk2 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103582637A (zh) * 2011-05-17 2014-02-12 弗·哈夫曼-拉罗切有限公司 酪氨酸激酶抑制剂
US20140161801A1 (en) * 2011-05-26 2014-06-12 Xuanzhu Pharma Co., Ltd. Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof
CN103958478A (zh) * 2011-11-30 2014-07-30 霍夫曼-拉罗奇有限公司 新双环二氢异喹啉-1-酮衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140131955A (ko) * 2012-03-09 2014-11-14 카나 바이오사이언스 인코포레이션 신규 트리아진 유도체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103582637A (zh) * 2011-05-17 2014-02-12 弗·哈夫曼-拉罗切有限公司 酪氨酸激酶抑制剂
US20140161801A1 (en) * 2011-05-26 2014-06-12 Xuanzhu Pharma Co., Ltd. Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof
CN103958478A (zh) * 2011-11-30 2014-07-30 霍夫曼-拉罗奇有限公司 新双环二氢异喹啉-1-酮衍生物

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071448A (zh) * 2017-01-22 2018-12-21 福建广生堂药业股份有限公司 Ask1抑制剂及其制备方法和应用
CN109071448B (zh) * 2017-01-22 2020-03-17 福建广生堂药业股份有限公司 Ask1抑制剂及其制备方法和应用
US10787435B2 (en) 2017-01-22 2020-09-29 Fuijan Cosunter Pharmaceutical Co. Ltd. ASK1 inhibitor and preparation method and use thereof
CN110294742A (zh) * 2018-03-21 2019-10-01 山东轩竹医药科技有限公司 并环类ask1抑制剂及其应用
CN110294742B (zh) * 2018-03-21 2023-01-31 山东轩竹医药科技有限公司 并环类ask1抑制剂及其应用
CN111808079A (zh) * 2020-08-05 2020-10-23 中国药科大学 吲哚类ask1小分子抑制剂及其制备方法和应用
CN113234053A (zh) * 2021-05-30 2021-08-10 吉林农业大学 裂环羽扇豆烷衍生物及在制备ask1抑制剂中的应用

Also Published As

Publication number Publication date
WO2018149284A1 (zh) 2018-08-23
CN109071498B (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
CN109071498A (zh) 激酶抑制剂及其制备方法和用途
EP2683710B1 (en) Soluble guanylate cyclase activators
TWI675026B (zh) 稠環衍生物、其製備方法、中間體、藥物組合物及應用
KR20220017917A (ko) Thr-베타의 조절제 및 이의 사용 방법
WO2018166493A1 (zh) 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
AU2014267974B2 (en) Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
AU2013356894B2 (en) Imidazopyridazine derivatives as GABAA receptor modulators
WO2019134539A1 (zh) 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
WO2016169421A1 (zh) 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
CA2710452A1 (en) Imidazo [1,2-a] pyridine compounds
JP7035118B2 (ja) ラクタム化合物誘導体およびその応用
WO2022121813A1 (zh) Sos1抑制剂、包含其的药物组合物及其用途
WO2022028506A1 (zh) Sos1抑制剂、包含其的药物组合物及其用途
US20180312475A1 (en) Aldosterone synthase inhibitors
JP6914974B2 (ja) 腎疾患、心血管疾患、および線維性障害の治療に有用な二環式イミダゾール誘導体
EP4093384A1 (en) Novel cell metabolism modulating compounds and uses thereof
WO2021073498A1 (zh) Egfr抑制剂、组合物及其制备方法
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
KR20150079677A (ko) 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물
JP2023545452A (ja) クリプトスポリジウム症の治療のための化合物及び組成物
JP2022527279A (ja) キノリン誘導体及び癌の治療のためのその使用
WO2024067463A1 (zh) 苯并[7]环烯类衍生物、包含其的药物组合物及其医药用途
WO2022171126A1 (zh) 作为Wee-1抑制剂的稠环化合物
WO2022171128A1 (zh) 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022156788A1 (zh) 苯并咪唑化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant